The quarter modestly beat the limited EPS expectation. Kyverna reported a $0.63 per-share loss versus published estimates clustered around roughly $0.69–$0.73, a narrow beat rather than a major earnings surprise.
| Metric | Q2 2026 | Q2 2025 | Read-through |
|---|---|---|---|
| R&D expense | $24.8M (Financial Results) | $35.8M (Statements of Operations) | Lower as SPS work advances toward filing |
| G&A expense | $14.8M (Financial Results) | $8.6M (Statements of Operations) | Higher commercial and corporate investment |
| Net loss | $38.3M (Financial Results) | $42.1M (Statements of Operations) | Loss narrowed year over year |
| Loss per share | $0.63 (Statements of Operations) | $0.97 (Statements of Operations) | Better partly because share count increased |
| Cash, equivalents and marketable securities | $199.4M (Financial Results) | $279.3M at Dec. 31, 2025 (Condensed Balance Sheets) | Cash declined materially, though runway remains into 2028 |
The more important update is a new regulatory option in progressive MS. FDA RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis adds a third RMAT indication and creates potential access to more intensive FDA interaction, rolling review and accelerated-approval pathways. That is genuinely incremental versus the prior setup, although the filing provides no new efficacy dataset and defers the development strategy until early 2027 (Progressive Multiple Sclerosis Strategy).
The lead SPS program remains on schedule, not ahead of it. Kyverna has submitted the CMC portion of its rolling BLA and still expects to complete the submission in Q4 2026, with 12-month KYSA-8 data due in Q3 2026. The filing also reiterates mid-2027 completion of Phase 3 gMG enrollment. These milestones preserve the expected timeline but do not pull forward approval or commercial launch certainty (SPS Rolling BLA Submission; Enrollment Ongoing in KYSA-6).
Net, the filing improves the pipeline narrative more than the near-term financial picture. The small EPS beat and narrower loss are secondary to the naSPMS RMAT designation, which broadens miv-cel’s potential market and regulatory leverage. Against expectations, this is a modestly favorable update: a new clinical-regulatory opportunity and intact execution, offset by continued cash consumption and no disclosed clinical results or accelerated timeline.
Read the original 8-K on SEC EDGAR ↗